AL-78898A clinical trials
Also written AL-78898A.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses AL-78898A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Alcon Research (2) · Potentia Pharmaceuticals, Inc. (1)
Studies
Open first, then newest update. How each study uses AL-78898A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)TerminatedPhase 2Alcon ResearchNCT01603043Written as Al-78898AHow we know
- Evaluation of AL-78898A in Exudative Age-Related Macular DegenerationCompletedPhase 2Alcon ResearchNCT01157065Written as AL-78898AHow we know
- Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)CompletedPhase 1Potentia Pharmaceuticals, Inc.NCT00473928Written as POT-4How we know